<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386526</url>
  </required_header>
  <id_info>
    <org_study_id>APG-1387-US-001</org_study_id>
    <nct_id>NCT03386526</nct_id>
  </id_info>
  <brief_title>APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies</brief_title>
  <official_title>A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as a Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      APG-1387 is a potent, bivalent small-molecule Inhibitor of Apoptosis Protein (IAP)&#xD;
      antagonist. APG-1387 has shown strong dose- and schedule-dependent antitumor activities in&#xD;
      multiple human cancer xenograft models, APG-1387 also demonstrates its synergistic effect in&#xD;
      combination with immune checkpoint inhibitor anti-PD-1 antibody, and such a combinatory&#xD;
      effect was further enhanced by chemotherapeutic agent. A total of 35 patients with advanced&#xD;
      solid tumors or lymphomas have been treated with APG-1387 in two Phase I dose-escalation&#xD;
      studies in Australia and in China. Ten dose levels have been tested ranging from 0.3 mg to 45&#xD;
      mg in these two studies. Based on the preliminary results, APG-1387 is well-tolerated at the&#xD;
      dose levels evaluated to date. APG-1387 is intended for the treatment of patients with&#xD;
      advanced solid tumors and hematologic malignancies. After establishing the maximum tolerated&#xD;
      dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several&#xD;
      Ib /II studies will be implemented accordingly to further access the antitumor effects of&#xD;
      APG-1387 in combination with either pembrolizumab or the chemotherapeutic agents.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>18-24 months</time_frame>
    <description>Patients with APG-1387 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor effects of APG-1387 as a single agent</measure>
    <time_frame>18-24 months</time_frame>
    <description>Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1 or the Revised Response Criteria for Malignant Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation</measure>
    <time_frame>18-24 months</time_frame>
    <description>Maximum plasma concentration (Cmax) will be assessed in the patients treated with APG-1387</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor effects of APG-1387 in combination with pembrolizumab or combination with paclitaxel and carboplatin in patients with advanced solid tumors</measure>
    <time_frame>18-24 months</time_frame>
    <description>Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1 or the Revised Response Criteria for Malignant Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary biomarker assessment</measure>
    <time_frame>18-24 months</time_frame>
    <description>Tumor biopsy and peripheral blood sample at baseline and 15-21 days after administration of APG-1387 alone or in combination with systemic anti-cancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation</measure>
    <time_frame>18-24 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of APG-1387 will be assessed on patients treated with APG-1387</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Solid Tumors or Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>APG-1387 for Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-1387 for Injection</intervention_name>
    <description>Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle</description>
    <arm_group_label>APG-1387 for Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed solid tumor or hematological malignancies&#xD;
&#xD;
          2. Life expectancy ≥ 3 months&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2&#xD;
&#xD;
          4. Corrected QT interval (QTc) ≤ 450 ms in males, and ≤ 470 ms in females&#xD;
&#xD;
          5. Adequate hematologic function&#xD;
&#xD;
          6. International normalized ratio (INR), prothrombin time (PT) or activated partial&#xD;
             thromboplastin time (aPTT) ≤1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          7. Adequate renal and liver function&#xD;
&#xD;
          8. Willingness to use contraception&#xD;
&#xD;
          9. Ability to understand and willingness to sign a written informed consent form&#xD;
&#xD;
         10. Willingness and ability to comply with study procedures and follow-up examination&#xD;
&#xD;
         11. Have provided tissue for biomarker analysis from a newly or recently-obtained biopsy&#xD;
             of a tumor lesion not previously irradiated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior&#xD;
             to entering the study&#xD;
&#xD;
          2. Received hormonal, biologic (&lt; 2 half-lives), small molecule targeted therapies or&#xD;
             other anti-cancer therapy within 21 days of study entry&#xD;
&#xD;
          3. Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days&#xD;
             of study entry&#xD;
&#xD;
          4. Has known active central nervous (CNS) metastases and/or carcinomatous meningitis.&#xD;
             Patients who have received prior radiotherapy for previous brain metastasis must have&#xD;
             discontinued steroids for 14 days prior to study entry and be clinically stable&#xD;
&#xD;
          5. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not&#xD;
             recover to ≤ Grade 1 except alopecia&#xD;
&#xD;
          6. Requirement for corticosteroid treatment, with the exception of megestrol, local use&#xD;
             of steroid&#xD;
&#xD;
          7. Use of therapeutic anticoagulants&#xD;
&#xD;
          8. International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≥&#xD;
             1.5 x ULN&#xD;
&#xD;
          9. Concurrent treatment with an investigational agent or device within 28 days prior to&#xD;
             the first dose of therapy&#xD;
&#xD;
         10. Unstable angina, myocardial infarction, or a coronary revascularization procedure&#xD;
             within 180 days of study entry&#xD;
&#xD;
         11. Neurologic instability per clinical evaluation due to tumor involvement of the central&#xD;
             nervous system (CNS)&#xD;
&#xD;
         12. History of Bell's palsy&#xD;
&#xD;
         13. Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic&#xD;
             infections, or any other disease or condition associated with chronic inflammation&#xD;
&#xD;
         14. Active infection requiring systemic antibiotic/ antifungal medication&#xD;
&#xD;
         15. Known or suspected Wilson's Disease&#xD;
&#xD;
         16. Prior treatment with IAP inhibitors&#xD;
&#xD;
         17. History of hypersensitivity to paclitaxel, or any therapeutic antibody&#xD;
&#xD;
         18. Has an active autoimmune disease, or a documented history of autoimmune disease, or a&#xD;
             syndrome that requires systemic steroids or immunosuppressive agents&#xD;
&#xD;
         19. Is on chronic systemic steroid therapy&#xD;
&#xD;
         20. Has received a live vaccine within 30 days prior to first dose&#xD;
&#xD;
         21. Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow&#xD;
             transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifan Zhai, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ascentage Pharma Group Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Shantz</last_name>
    <phone>301-802-3414</phone>
    <email>kate.shantz@ascentage.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nehal Lakhani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The START Center for Cancer Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5265</phone>
      <email>Isabel.Jimenez@startsa.com</email>
    </contact>
    <investigator>
      <last_name>Drew Rasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IAP inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

